Item 2.02. Results of Operations and Financial Condition.

On January 10, 2022, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing preliminary, unaudited ORLADEYO® (berotralstat) revenue for the fourth quarter and full year ended December 31, 2021 and providing new guidance for full year 2022 ORLADEYO net revenue and expected peak ORLADEYO sales. The press release also referenced a previously announced, upcoming webcast presentation by the Company at the 40th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on January 10, 2022 at 9:45 a.m. ET. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein.

The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.



Exhibit No.   Description

                Press release dated January 10, 2022 entitled "BioCryst Announces
  99.1        Preliminary Full Year 2021 ORLADEYO® (berotralstat) Net Revenue and
              Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales
              Guidance"

104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses